Shows
EHA UnpluggedHematology Portraits: prof. Martin DreylingIn this episode, we sit down with prof. Martin Dreyling from the Ludwig-Maximilians-University in Munich who talks about his professional journey in hematology as a clinician and a researcher. Listen to prof. Dreyling as he recalls his contributions to the field of lymphoma, and in particular mantle cell lymphoma, that resulted in novel therapeutic approaches. The ongoing emphasis on the cross-border teamwork in clinical trials and the importance of European cooperation highlights the impact that these initiatives had on prof. Dreyling’s career. Tune in to hear his thoughts about the future directions in lymphoma tr...2025-05-2323 min
The HematologistA Leap of Faith? Elimination of Autologous Stem Cell Transplantation for Patients With Mantle Cell Lymphoma in First RemissionIn this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Martin Dreyling, MD, a professor of medicine and head of the lymphoma program at LMU Hospital in Munich. They discuss the TRIANGLE trial, conducted by Dr. Dreyling and colleagues, for the European Mantle Cell Lymphoma Network. 2024-09-1621 min
Hämatologie ShortcastsDKK2024: Prof. Dr. Martin Dreyling - Ein Par-Force-Ritt durch die malignen B-Zell LymphomeDr. Andreas Hausmann und Dr. Richard Schabath im Gespräch mit Prof. Dr. Martin Dreyling, Leiter des Zentrums für maligne Hämatologie, der LMU München Campus Großhadern (CCC München LMU).Ein Par-Force-Ritt durch die malignen B-Zell Lymphome:Mantelzellymphom: Die Triangle Studie, die Beantragung von Ibrutinib im Alltag, die Bedeutung der autologen Blutstammzelll-Transplantation beim Mantelzellymphom. Welche Therapie ist im Rezidiv indiziert und ändert sich die First Line Therapie evtl. nochmals in der näheren Zukunft?Follikuläres Lymphom:Kommt es zur Chemotherapie-freien Firstline Therapie? Gibt es ein Reviva...2024-03-0830 min
Oncology On The GoUnraveling Resistance and Heterogeneity in Mantle Cell Lymphoma ManagementAlthough strides have been made with Bruton tyrosine kinase (BTK) inhibitors and CAR-T cell therapy, relapse and resistance remain significant hurdles in treating patients with mantle cell lymphoma (MCL). The Lymphoma Research Foundation's 2023 MCL Scientific Consortium and Workshop addressed these complexities, aiming to dissect the intricate biology of MCL and propel progress towards a cure.
CancerNetwork® spoke with leaders in the MCL field to better understand the aim of the consortium and the advancements they hope to see in the space. The journal ONCOLOGY® published these findings in the February 2024 issue. The interviews included Elias Campo, MD, PhD...2024-02-0511 min
PeerView Clinical Pharmacology CME/CNE/CPE VideoProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14
PeerView Internal Medicine CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14
PeerView Internal Medicine CME/CNE/CPE Video PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14Hämatologie ShortcastsFokus Mantelzelllymphom - Experteninterview: Prof. Dr. Martin DreylingDr. Andreas Hausmann im Gespräch mit Prof. Dr. med. Martin Dreyling:Dr. Martin Dreyling ist Professor der medizinischen Fakultät der Ludwig Maximilians Universität München und Oberarzt der Medizinischen Klinik III am Campus Großhadern.Er studierte Medizin an den Universitäten in Düsseldorf, Gießen, Tübingen und Würzburg und spezialisierte sich im Anschluss auf den Schwerpunkt Hämatologie und Onkologie an den Universitäten in Bonn, Münster, Göttingen und München. Von 1992 bis 1995 arbeitete er darüber hinaus als Wissenschaftler in der Abteilung Hämatologie/Onkologie an der Universitä...2023-07-1337 min
Blood Cancer TalksEpisode 21. Newly Diagnosed Mantle Cell LymphomaIn this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes:2:11 How to diagnose mantle cell lymphoma (MCL)?6:51 Clinical manifestations of mantle cell lymphoma7:52 How to manage leukemic variant of MCL? 12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with low Ki-67?17:21 Overview on treatment of newly diagnosed MCL19:03 Are all cytarabine-based regimens for MCL created equally? RCT of Autologous Transplantation in MCL: https://pubmed.ncbi.nlm.nih.gov/15591112/...2023-05-0346 min
EHA UnpluggedWhat's in Store for Lymphoid Malignancies?In this episode, guest Prof Martin Dreyling and host Dr Nathalie van Havre discuss the latest developments in lymphoid malignancies and the research roadmap that has been put in place to guide future research.Professor Dreyling highlights the move away from traditional chemotherapy towards non-cytostatic approaches and discusses the long-term complications of traditional treatments and the need for precision therapy.Host: Dr Nathalie van Havre; Guest: Prof Martin DreylingLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.2023-03-3118 min
Lymphom Kompetenz KOMPAKT – Expertinnen diskutieren Lymphome & LeukämienMCL: BTK-Inhibition vs. HD-Therapie?In dieser Podcastfolge diskutieren wir über die Therapie beim Mantelzell-Lymphom. Zwei Fragestellungen sind dabei zentral: Zum einen: Wer ist eigentlich therapiebedürftig - also wer hat eine dringende Indikation um eine Therapie zu begrinnen und bei wem kann man warten? Und damit eng zusammenhängend: Kann man diese Entscheidungen mit dem MIPI-c treffen oder brauchen wir den p53 Status vor der Therapieeinleitung auch bei der Erstlinientherapie? Zum anderen: Wenn dann die Entscheidung für eine Therapie getroffen wird, ist dann die BTKInhibition anstelle der Hochdosis-Chemotherapie die bessere Option für alle jungen Patient:innen? Diese Fragen stehen im Mittelpunkt dieses Podca...2023-01-2724 min
Cancer.Net PodcastLymphoma Highlights from the 2022 American Society of Hematology Annual Meeting, with Christopher Flowers, MDASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The me...2023-01-2608 min
Audio Journal of Oncology PodcastAUDIO JOURNAL OF ONCOLOGY—Ibrutinib Enables Transplant-Free Therapy for Mantle Cell LymphomaIbrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma
NEW ORLEANS, USA—Many patients eligible for autologous stem cell transplantation for their mantle cell lymphoma (under current best practice recommendations) could be treated as effectively—and potentially with less toxicity—with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, according to findings from Munich, Germany.
The Randomized Triangle Trial, conducted by the European Mantle Cell Lymphoma Network, reported positive findings about a transplant-free approach to the American Society of Hematology 2022 Annual Meeting.
https://ashpublications.org/blood/article/140/Supplement%201/1/490022/Efficacy-and-Safety-of-Ibrutinib-Combined-with
Audio Journal of Oncology...2023-01-2016 minEHA UnpluggedPapers Unplugged: Is CAR-T Economically Sustainable?Is CAR-T economically sustainable?Join our guest Prof Martin Dreyling and host Dr Nathalie van Havre as they discuss the costs of CAR-T cell therapy for the treatment of blood disorders at an individual level and whether it is economically sustainable for health systems.Listen along as they consider the financial challenges of patient selection for this costly life-saving therapy, based on Prof Dreyling’s experience with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) patients. Challenges touched upon include reimbursement policies, time lags and associated costs of personalized therapy, and choosing the indications to in...2023-01-1317 min
EHA UnpluggedPatient Support: Relate and Create (Clinical Trial)In the third episode of the Clinical Trial podcasts, Prof. Martin Dreyling from the University of Munich makes several points about standards of care in clinical studies, also mentioned as GCPs (Good Clinical Practices). He gives us a historical perspective on the establishment of these standards 20 years ago, and how they need an update through what he calls a ‘reality check’. Prof. Dreyling is part of the coalition Reducing Bureaucracy in Clinical Trials and explains what they are proposing to update and improve GCPs in 2021.In this series of Clinical Trial podcasts produced by EHA, experts unravel for...2022-02-0117 min
Audio Medica News - Medical News InterviewsONCOLOGY: Combinations and Targeted Agents: Better Survival in Mantle Cell LymphomaAudio Journal of Oncology, February 26th, 2008
Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma
MARTIN DREYLING, University Hospital Grosshaden, Munich
REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.2008-02-2906 min